Tetra Bio-Pharma expands phase-3 trial,
Clinical-trial sites in 20 Canadian and 20 American locations
This is a 4-week randomized, double-blind, placebo-controlled, parallel group design trial to evaluate the safety and efficacy of inhaled PPP001 on uncontrolled cancer pain in patients with symptoms related to advanced incurable cancer.
Accelerate patient recruitment
Access health-related quality-of-life for advanced-cancer-pain patients
Expedite Tetra’s submission to regulatory agencies
Health-Canada-approved Class 2 medical device
Vaporizer delivery mechanism more acceptable to hospitals and palliative care centres
Preparing for commercialization, and for regulatory filing purposes, Tetra is branding its cannabinoid-derived drug under the commercial trademark CAUMZ (formerly referred to as PPP-001).
“I look forward to the day when Tetra’s cannabinoid-derived drugs will help reduce, if not eliminate the reliance on drugs like Fentanyl(R), Oxycodone(R) or morphine and that hopefully the study drug will be able to bring serenity to patients in their difficult journey through the disease.”
“I am extremely pleased with Tetra’s ability to quickly resolve the problem that required us to suspend our clinical trial in advanced cancer pain,” said Tetra CEO and CSO Dr. Guy Chamberland.
“The continuation of our research is excellent news, not only for those suffering with advanced cancer pain and other symptoms but also for our investors,” he said.
“With great challenge comes great opportunity and what we are now able to deliver is a better and more reliable product.”
ABOUT TETRA BIO-PHARMA
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
The company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements.
The company is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.